EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urea-Based Prodrugs Improve Systemic Mebendazole Exposure After Oral Administration

Katarina Färnegårdh, Richard Svensson, Prasad Wakchaure, Johanna Larsson, Christoffer Bengtsson, Claes Andersson, Rolf Larsson, Peter Nygren, Ylva Gravenfors, Mårten Fryknäs

Pharmaceutics · 09.11.2026 · 18 (11) · 1450

DOI: 10.3390/pharmaceutics18111450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 09.11.2026. Verfasst von Katarina Färnegårdh und 9 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Erling-Persson Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Mebendazole (MBZ) is an established anthelmintic drug with emerging therapeutic potential in oncology and immunology, but its broader clinical utility is constrained by poor aqueous solubility and extensive first-pass metabolism, resulting in low and variable systemic exposure.

Methods

Here, we synthesized and profiled in vitro a series of solubility-enhanced, urea-based MBZ prodrugs designed to favor intact absorption across the intestinal epithelium followed by systemic release of parent MBZ.

Results

Optimized candidates exhibited markedly improved solubility under simulated intestinal conditions and a favorable metabolic profile, including reduced intestinal metabolism compared with MBZ. In mouse pharmacokinetic studies, oral administration of selected prodrugs increased systemic MBZ exposure relative to equimolar doses of MBZ. Administration of the lead prodrug 2i resulted in an approximately 10-fold higher peak MBZ concentration (Cmax) and approximately 2-fold higher MBZ exposure (area under the plasma concentration–time curve, AUC) compared with an equimolar dose of MBZ. These differences should be interpreted in light of the different dosing formulations, with the prodrug administered as a solution and MBZ as a suspension.

Conclusions

These findings provide in vivo proof-of-concept that urea-based prodrugs may improve systemic MBZ exposure following oral administration and support further evaluation of this strategy for indications requiring systemic drug exposure.

Förderung

  • Swedish Cancer Society
  • Erling-Persson Foundation

Zitieren

APA

Färnegårdh, K., Svensson, R., Wakchaure, P., Larsson, J., Bengtsson, C., Andersson, C., Larsson, R., Nygren, P., Gravenfors, Y., & Fryknäs, M. (2026). Urea-Based Prodrugs Improve Systemic Mebendazole Exposure After Oral Administration. Pharmaceutics, 18(11), 1450. https://doi.org/10.3390/pharmaceutics18111450

Vancouver

Färnegårdh K, Svensson R, Wakchaure P, Larsson J, Bengtsson C, Andersson C, et al. Urea-Based Prodrugs Improve Systemic Mebendazole Exposure After Oral Administration. Pharmaceutics. 2026;18(11):1450. doi:10.3390/pharmaceutics18111450

BibTeX
@article{Frnegrdh2026,
  author = {Färnegårdh, Katarina and Svensson, Richard and Wakchaure, Prasad and Larsson, Johanna and Bengtsson, Christoffer and Andersson, Claes and Larsson, Rolf and Nygren, Peter and Gravenfors, Ylva and Fryknäs, Mårten},
  title = {Urea-Based Prodrugs Improve Systemic Mebendazole Exposure After Oral Administration},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1450},
  doi = {10.3390/pharmaceutics18111450}
}
Kostenlos starten →